The role of airways microbiota on local and systemic diseases: a rationale for probiotics delivery to the respiratory tract.
暂无分享,去创建一个
[1] Xikun Zhou,et al. Lung microbiome: new insights into the pathogenesis of respiratory diseases , 2024, Signal transduction and targeted therapy.
[2] David M. Holtzman,et al. Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies , 2024, Experimental & molecular medicine.
[3] P. Capaccio,et al. Topical administration of S. salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial , 2023, European journal of pediatrics.
[4] V. Fainardi,et al. Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa. , 2023, International journal of antimicrobial agents.
[5] A. Castaldo,et al. Lung Microbiome as a Treatable Trait in Chronic Respiratory Disorders , 2023, Lung.
[6] Thuy T B Phung,et al. Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics , 2023, Scientific reports.
[7] O. Sheils,et al. The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs , 2023, International journal of molecular sciences.
[8] G. Maisetta,et al. Lactobacillus Probiotic Strains Differ in Their Ability to Adhere to Human Lung Epithelial Cells and to Prevent Adhesion of Clinical Isolates of Pseudomonas aeruginosa from Cystic Fibrosis Lung , 2023, Microorganisms.
[9] N. Yuksel,et al. Lung Microbiota: Its Relationship to Respiratory System Diseases and Approaches for Lung-Targeted Probiotic Bacteria Delivery , 2023, Molecular pharmaceutics.
[10] C. Greene,et al. Basic, translational and clinical aspects of bronchiectasis in adults , 2023, European Respiratory Review.
[11] Fang Wang,et al. Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study , 2023, Scientific Reports.
[12] L. Segal,et al. Microbial inflammatory networks in bronchiectasis exacerbators with Pseudomonas aeruginosa. , 2023, Chest.
[13] Y. Ke,et al. The Lung Microbiome: A New Frontier for Lung and Brain Disease , 2023, International journal of molecular sciences.
[14] A. Ceppe,et al. Antibiotic Tolerance and Treatment Outcomes in Cystic Fibrosis Methicillin-Resistant Staphylococcus aureus Infections , 2022, Microbiology spectrum.
[15] Marc Schneider,et al. Probiotic Formulation Development and Local Application with Focus on Local Buccal, Nasal and Pulmonary Application , 2022, Current Nutraceuticals.
[16] Z. Ren,et al. The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment , 2022, Frontiers in Immunology.
[17] A. Consonni,et al. Approaching the Gut and Nasal Microbiota in Parkinson’s Disease in the Era of the Seed Amplification Assays , 2022, Brain sciences.
[18] M. Surette,et al. Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation , 2022, Journal of the Pediatric Infectious Diseases Society.
[19] Luodan Yang,et al. The Lung Microbiome: A Potential Target in Regulating Autoimmune Inflammation of the Brain , 2022, Neuroscience Bulletin.
[20] X. Yi,et al. The human lung microbiome—A hidden link between microbes and human health and diseases , 2022, iMeta.
[21] Cuiming Zhu,et al. The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases , 2022, Frontiers in Immunology.
[22] B. Marsland,et al. The lung-brain axis: A new frontier in host-microbe interactions. , 2022, Immunity.
[23] B. G. Andrade,et al. The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19 , 2022, Bioscience of microbiota, food and health.
[24] Z. Bagheri,et al. Roles of Microbiota in Cancer: From Tumor Development to Treatment , 2022, Journal of oncology.
[25] T. Gurley,et al. Age-Related Changes in the Nasopharyngeal Microbiome Are Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Symptoms Among Children, Adolescents, and Young Adults , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Jianchao Wei,et al. Targeting the Pulmonary Microbiota to Fight against Respiratory Diseases , 2022, Cells.
[27] G. Maisetta,et al. Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option? , 2022, Antibiotics.
[28] A. Flügel,et al. The lung microbiome regulates brain autoimmunity , 2022, Nature.
[29] A. Cervin,et al. Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo‐controlled crossover trial , 2022, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[30] G. Huffnagle,et al. The Lung Microbiome during Health and Disease , 2021, International journal of molecular sciences.
[31] Catherine Burke,et al. Manipulation of the Upper Respiratory Microbiota to Reduce Incidence and Severity of Upper Respiratory Viral Infections: A Literature Review , 2021, Frontiers in Microbiology.
[32] M. Pariano,et al. Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection. , 2021, International journal of pharmaceutics.
[33] R. Capasso,et al. Involvement of Probiotics and Postbiotics in the Immune System Modulation , 2021, Biologics.
[34] Gui-yuan Li,et al. Lung microbiome alterations in NSCLC patients , 2021, Scientific Reports.
[35] H. Wei,et al. Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19 , 2021, Virologica Sinica.
[36] P. Zinzani,et al. Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy , 2021, Annals of clinical and translational neurology.
[37] M. López-Pérez,et al. Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19 , 2020, bioRxiv.
[38] Jing-quan Li,et al. Microbiome dysbiosis in lung cancer: from composition to therapy , 2020, npj Precision Oncology.
[39] S. Lebeer,et al. Probiotic nasal spray development by spray drying. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[40] J. Madrenas,et al. Intranasal Application of Lactococcus lactis W136 Is Safe in Chronic Rhinosinusitis Patients With Previous Sinus Surgery , 2020, Frontiers in Cellular and Infection Microbiology.
[41] F. Inchingolo,et al. The Human Respiratory System and its Microbiome at a Glimpse , 2020, Biology.
[42] J. E. Aguilar-Toalá,et al. Postbiotics and paraprobiotics: From concepts to applications. , 2020, Food research international.
[43] Ran Wang,et al. Microbiota Imbalance Contributes to COPD Deterioration by Enhancing IL-17a Production via miR-122 and miR-30a , 2020, Molecular therapy. Nucleic acids.
[44] P. Gosset,et al. Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice , 2020, BMC microbiology.
[45] Hideki Takahashi,et al. The Ability of Respiratory Commensal Bacteria to Beneficially Modulate the Lung Innate Immune Response Is a Strain Dependent Characteristic , 2020, Microorganisms.
[46] G. Héry-Arnaud,et al. The Microbiome in Cystic Fibrosis Pulmonary Disease , 2020, Genes.
[47] B. Gu,et al. Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms , 2020, Translational lung cancer research.
[48] R. Weichselbaum,et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling , 2020, The Journal of experimental medicine.
[49] L. Delhaes,et al. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks , 2020, Frontiers in Cellular and Infection Microbiology.
[50] H. Xiong,et al. Spray drying of Lactobacillus rhamnosus GG with calcium-containing protectant for enhanced viability , 2019 .
[51] Chenxiao Hu,et al. Microbiome Multi-Omics Network Analysis: Statistical Considerations, Limitations, and Opportunities , 2019, Front. Genet..
[52] K. Koskinen,et al. The microbiome of the upper respiratory tract in health and disease , 2019, BMC Biology.
[53] A. Amedei,et al. The lung microbiome: clinical and therapeutic implications , 2019, Internal and Emergency Medicine.
[54] Tomasz P. Wypych,et al. The influence of the microbiome on respiratory health , 2019, Nature Immunology.
[55] H. Richardson,et al. The microbiome in bronchiectasis , 2019, European Respiratory Review.
[56] M. Surette,et al. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[57] J. Greenland,et al. Parkinson’s Disease: Pathogenesis and Clinical Aspects , 2018 .
[58] L. Drago,et al. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract , 2018, BMC Infectious Diseases.
[59] MingKun Li,et al. Transcriptionally Active Lung Microbiome and Its Association with Bacterial Biomass and Host Inflammatory Status , 2018, mSystems.
[60] G. DeLuca,et al. Invited Review: From nose to gut – the role of the microbiome in neurological disease , 2018, Neuropathology and applied neurobiology.
[61] S. Guglielmetti,et al. Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. , 2018, Cell reports.
[62] D. Descamps,et al. Paradigms of Lung Microbiota Functions in Health and Disease, Particularly, in Asthma , 2018, Front. Physiol..
[63] S. Lebeer,et al. Enhancing the viability of Lactobacillus rhamnosus GG after spray drying and during storage. , 2017, International journal of pharmaceutics.
[64] A. Cervin,et al. Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: A randomized controlled trial , 2017, Laryngoscope investigative otolaryngology.
[65] W. T. Harris,et al. Airway microbiota across age and disease spectrum in cystic fibrosis , 2017, European Respiratory Journal.
[66] P. Sly,et al. Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children , 2017, Respirology.
[67] G. Jan,et al. Spray drying of probiotics and other food-grade bacteria: A review , 2017 .
[68] E. Pekkonen,et al. Oral and nasal microbiota in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[69] Wouter A. A. de Steenhuijsen Piters,et al. The microbiota of the respiratory tract: gatekeeper to respiratory health , 2017, Nature Reviews Microbiology.
[70] M. Moffatt,et al. Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients , 2017, PloS one.
[71] M. Surette,et al. Composition and immunological significance of the upper respiratory tract microbiota , 2016, FEBS letters.
[72] You-Wen He,et al. Lung inflammation stalls Th17-cell migration en route to the central nervous system during the development of experimental autoimmune encephalomyelitis. , 2016, International immunology.
[73] R. Fuchs,et al. Mechanism of human rhinovirus infections , 2016, Molecular and Cellular Pediatrics.
[74] H. Smyth,et al. Inhaled Biologics: From Preclinical to Product Approval. , 2016, Current pharmaceutical design.
[75] J. Erb-Downward,et al. Homeostasis and its disruption in the lung microbiome. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[76] S. Brix,et al. Chronic obstructive pulmonary disease and asthma‐associated Proteobacteria, but not commensal Prevotella spp., promote Toll‐like receptor 2‐independent lung inflammation and pathology , 2015, Immunology.
[77] J. Phillips. Polio , 2015, Workplace health & safety.
[78] Amy M. Sheflin,et al. Cancer-Promoting Effects of Microbial Dysbiosis , 2014, Current Oncology Reports.
[79] M. Caetano,et al. T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.
[80] M. Lynch,et al. Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice , 2014, Neurobiology of Aging.
[81] E. Sanders,et al. Viral and Bacterial Interactions in the Upper Respiratory Tract , 2013, PLoS pathogens.
[82] R. Spang,et al. T cells become licensed in the lung to enter the central nervous system , 2012, Nature.
[83] F. Spertini,et al. Intragastric and Intranasal Administration of Lactobacillus paracasei NCC2461 Modulates Allergic Airway Inflammation in Mice , 2012, International journal of inflammation.
[84] K. Kristensson. Microbes' roadmap to neurons , 2011, Nature Reviews Neuroscience.
[85] John E. Scott,et al. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.
[86] K Roos,et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media , 2008, Archives of Disease in Childhood.
[87] J. Ager,et al. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. , 2005, Microbial pathogenesis.
[88] H. Scheiblauer,et al. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. , 1992, The Journal of infectious diseases.